Treating diabetes during pregnancy can break link to childho...(. This suggests that the 'metabolic impr...),Health
Home
Biology
Medicine
Technology
Products
News
Definition
Dictionary
Movies
Links
Tags
Search
RSS
Navigation Links
Biology News
Medicine News
Biology Products
Medicine Products
Biology Definition
Medicine Definition
Biology Technology
Medicine Technology
Biology Dictionary
Medicine Dictionary
HOME
>>
MEDICINE
>>
NEWS
Treating diabetes during pregnancy can break link to childhood obesity
. This suggests that the 'metabolic imprinting' for childhood obesity ......
http://www.bio-medicine.org/inc/biomed/medicine-news.asp
http://feeds.bio-medicine.org/latest-medical-news
Date:8/27/2007
. This suggests that the 'metabolic imprinting' for childhood obesity that results from gestational diabetes in pregnant women may be reversible," Hillier said.
'/>"/>
Contact: Danielle Cass
danielle.x.cass@kp.org
510-267-5354
Kaiser Permanente Division of Research
Source:
Eurekalert
0
GOOD
Page:
1
2
3
Related medicine news :
1
.
Gene Therapy shows promise in treating Hemophilia
2
.
Treating Depression In Children Could Lead To Poor Bone Development
3
.
Treating Epilepsy With Surgery
4
.
Treating Autism More Effectively
5
.
Stem Cell Therapy Effective For Treating Heart Attacks
6
.
Treating Leukemia With Natural Cells
7
.
Treating eye pain eases migraine
8
.
Treating wounds without stitches
9
.
Treating varicose veins
10
.
Treating acne with laser
11
.
Ketoconazole 2% more effective in treating Seborrheic Dermatitis
Post Your Comments:
*
Name:
*
Comment:
*
Email:
Breaking Medicine News(10 mins):
Health News:Surgery on beating heart thanks to robotic helping hand 2
Health News:Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented 2
Health News:Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented 3
Health News:Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented 4
Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 2
Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 3
Health News:PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management 2
Health News:PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management 3
Health News:PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management 4
Health News:Molecule Discovery Might Help ALS Patients 2
[
0
] Surgery on beating heart thanks to robotic helping hand
[
1
] Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented
[
0
] Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar
[
1
] PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management
[
0
] Molecule Discovery Might Help ALS Patients
Other Medicine News:
Health News:More Health Benefits from Organic milk 2
Health News:Sunscreen creams – use them appropriately 2
Health News:Scientists In UK Issue A Caution Over Untested Stem Cell Treatments 2
More Health Benefits from Organic milk
Sunscreen creams – use them appropriately
Scientists In UK Issue A Caution Over Untested Stem Cell Treatments
New Study To Find Means Of Reducing The Risk Of Diabetes In Youth
Improper Usage Of Sunscreen Can Harm Skin
Three Scottish Hospitals Fail To Meet Cleanliness Standards: NHS
Breaking Medicine Technology:
Within3 Expands into Mobile Applications 2
Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2
Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3
Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4
Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5
Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6
Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2
Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 1
Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 2
Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 3
Anxious Kids at Risk for Obesity in Adulthood 57251 1
Anxious Kids at Risk for Obesity in Adulthood 57251 2
The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 1
The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 2
[
0
] Within3 Expands into Mobile Applications
[
0
] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
[
0
] Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
Other Medicine Technology:
FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 2
FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 3
Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients 2
FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Medicine Products:
Allergen, Food, Ginger
Allergen, Food, Garlic
Allergen, Food, Flounder (plaice)
Allergen, Food, Egg YolkIgG
Biology Navigation
AIDS/HIV
Bioinformatics
Biotechnology
Biochemistry
Cancer
Cell Biology
Developmental Biology
Ecology
Environment
Evolution
Food Technology
Gene
Genetics
Genomics
Health/Medicine
Immunology
Microarray
Microbiology
Molecular
Marine Biology
Nanobiotechnology
Neurobiology
Plant Sciences
Stem Cell
Systems Biology
Virus
Women Health
Medical Navigation
Abortion
Aches
ADHD
Addiction
Alcohol
Allergy
Alternative Medicine
Alzheimer's Dementia
Anxiety/Stress
Arthritis
Autism
Bacteria
Blood
Bird Flu/Avian Flu
Bones
Breast Cancer
Cancer
Cardiovascular
Cervical Cancer
Chikungunya
Cholesterol
Clinical Trials
Colorectal Cancer
Conferences
Crohn's
Cystic Fibrosis
Dengue
Dentistry
Depression
Diabetes
Drug
Eating Disorders
Education
Epilepsy
Erectile Dysfunction
Eye Health/Blindness
Fertility
Flu/Cold
GastroIntestinal
Genetics
Gout
Headache/Migraine
Hearing/Deafness
HIV/AIDS
Huntington's Disease
Hypertension
Immune System/Vaccines
Insurance
Infectious Diseases
Irritable-Bowel Syndrome
Internet
Leukemia
Lifestyle
Liver Disease/Hepatitis
Lung Cancer
Lupus
Mad Cow Disease
Medical Devices
Medical Students/Training
Medicare/Medicaid
Medico
Men's health
Mental Health
MRI/Ultrasound
MRSA/Drug Resistance
Multiple Sclerosis
Muscular Dystrophy
Neurology
Nursing
Nutrition/Diet
Obesity/Weight Loss
Pain/Anesthetics
Parkinson's Disease
Pediatrics/Children's Health
Pharma/Biotech Industry
Pharmacy/Pharmacists
Pregnancy
Premature
Prostate
Psychology/Psychiatry
Rehabilitation
Respiratory/Asthma
SARS
Schizophrenia
Seniors/Aging
Sexual Health
Sleep/Sleep Disorders
Smoking
Statins
Stem Cell Research
Stroke
Surgery
Transplants/Organ Donations
Viruses
Water - Air Quality
Women's Health